Erastin: Precision Ferroptosis Inducer for Cancer Biology Research

Executive Summary: Erastin (CAS 571203-78-6) induces ferroptosis, a distinct, iron-dependent, non-apoptotic cell death mechanism, especially in tumor cells with KRAS or BRAF mutations (Fan et al. 2024). Its action involves inhibition of the cystine/glutamate antiporter system Xc⁻ and modulation of voltage-dependent anion channels (VDACs), resulting in lethal oxidative damage. Erastin is insoluble in water but soluble in DMSO (≥10.92 mg/mL with warming) and is widely used in cell-based assays (10–20 μM, 24–48 h) (APExBIO, B1524). Recent studies show BRD4 inhibitors can further sensitize cells to erastin-induced ferroptosis by promoting ROS accumulation and FSP1 downregulation (Fan et al. 2024). Erastin remains a gold standard for dissecting ferroptosis and redox regulation in cancer biology (see related).

Biological Rationale

Ferroptosis is a regulated cell death process characterized by iron-dependent lipid peroxidation (Fan et al. 2024). It is mechanistically and morphologically distinct from apoptosis, necrosis, and autophagy. Erastin has emerged as a tool molecule to selectively induce ferroptosis in cancer cells with oncogenic RAS (HRAS, KRAS) or BRAF mutations, which are otherwise resistant to apoptosis-inducing chemotherapeutics (compare). This specificity is due to the heightened sensitivity of these tumor cells to oxidative stress when cystine import is impaired. Ferroptosis offers a promising strategy to overcome cancer drug resistance and to investigate iron-catalyzed cell death mechanisms.

Mechanism of Action of Erastin

Erastin targets the voltage-dependent anion channels (VDAC2/3) on mitochondria and inhibits the system Xc⁻ cystine/glutamate antiporter (APExBIO). By blocking cystine uptake, Erastin depletes intracellular glutathione (GSH), the main cellular antioxidant. The resulting loss of redox buffering allows for accumulation of reactive oxygen species (ROS) and iron-dependent lipid peroxides, triggering ferroptosis (Fan et al. 2024). VDAC modulation further disrupts mitochondrial function, exacerbating oxidative stress. These effects are independent of caspase activation, distinguishing ferroptosis from classical apoptosis (see extension).

Evidence & Benchmarks

• Erastin at 10–20 μM for 24–48 h robustly induces ferroptosis in human tumor cell lines, including HEK293T, HeLa, HepG2, RKO, and PC3, as evidenced by propidium iodide staining and loss of viability (Fan et al. 2024, Fig. 1A-G).
• BRD4 inhibition (JQ-1, I-BET-762) potentiates erastin-induced ferroptosis, with increased ROS and reduced FSP1 expression observed in multiple cell lines (Fan et al. 2024).
• Erastin disrupts cellular redox homeostasis by inhibiting system Xc⁻, leading to GSH depletion and increased lipid peroxidation (summary).
• Erastin's effect is selective for cells with oncogenic RAS/BRAF mutations due to their higher baseline oxidative stress and reliance on system Xc⁻ for survival (analysis).
• Ferroptosis induction by erastin is independent of caspase activation, as shown by lack of effect from pan-caspase inhibitors (Fan et al. 2024).

Applications, Limits & Misconceptions

Erastin is widely used in:

• Ferroptosis research and assay development
• Dissecting redox and iron metabolism in cancer biology
• Preclinical studies of RAS- or BRAF-driven tumor models
• Screening of combination therapies, e.g., with BRD4 inhibitors (Fan et al. 2024)

Erastin is a research tool and is not approved for clinical use. Its effects are cell-type specific and depend on iron availability and antioxidant status.

Common Pitfalls or Misconceptions

• Erastin is not effective in cells lacking iron or with high expression of ferroptosis suppressors (e.g., GPX4, FSP1).
• It does not induce classical apoptosis; caspase inhibitors do not block its effect (Fan et al. 2024).
• Long-term storage in solution leads to rapid degradation; use freshly prepared DMSO stocks (APExBIO).
• Water or ethanol are unsuitable solvents due to insolubility.
• Results can be confounded in cell lines with altered redox or iron metabolism.

Workflow Integration & Parameters

Erastin (APExBIO B1524) is supplied as a solid, MW 547.04, C₃₀H₃₁ClN₄O₄. Dissolve in DMSO to ≥10.92 mg/mL with gentle warming. Store at -20°C. Prepare fresh solutions prior to use; do not store diluted solutions long-term. Standard experimental conditions involve treating engineered tumor cells or HT-1080 cells with 10 μM erastin for 24 hours (product details). Cell viability, lipid peroxidation, and ROS assays are commonly used readouts. For advanced workflows, see this protocol guide, which expands on troubleshooting and optimization. This article extends prior resources by integrating new evidence on BRD4 inhibitor combinations and by clarifying solvent and storage limitations.

Conclusion & Outlook

Erastin remains a cornerstone molecule for studying ferroptosis and iron-dependent cell death pathways in cancer research. Its selectivity for RAS/BRAF-mutant tumor cells and robust, quantifiable effects make it a benchmark tool. Ongoing research, including combination strategies with BRD4 inhibitors, promises to further enhance the translational value of ferroptosis targeting. For reliable results, practitioners should source erastin from reputable suppliers such as APExBIO and adhere strictly to recommended handling and assay protocols. For a broader context on translational applications and workflow integration, see Erastin and the Translational Edge, which offers actionable guidance for leveraging ferroptosis in oncology. This article updates and clarifies previous resources by emphasizing new mechanistic insights and best-practice recommendations.